NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Talaris Therapeutics Inc (NASDAQ: TALS)
TALS Technical Analysis
5
As on 9th Jun 2023 TALS STOCK Price closed @ 2.55 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 6.50 & Strong Sell for SHORT-TERM with Stoploss of 10.73 we also expect STOCK to react on Following IMPORTANT LEVELS. |
TALSSTOCK Price
Open | 2.53 | Change | Price | % |
High | 2.61 | 1 Day | 0.02 | 0.79 |
Low | 2.41 | 1 Week | -0.23 | -8.27 |
Close | 2.55 | 1 Month | -0.06 | -2.30 |
Volume | 262700 | 1 Year | -10.11 | -79.86 |
52 Week High 16.56 | 52 Week Low 0.94 |
NASDAQ USA Most Active Stocks
TSLA | 244.40 | 4.06% |
TTOO | 0.07 | -12.50% |
SOFI | 8.18 | 0.74% |
FFIE | 0.33 | 6.45% |
PONO | 1.72 | 2.38% |
AMD | 124.92 | 3.20% |
IDEX | 0.06 | 0.00% |
NKLA | 0.70 | 14.75% |
AMZN | 123.43 | -0.66% |
AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
TALS Daily Charts |
TALS Intraday Charts |
Whats New @ Bazaartrend |
TALS Free Analysis |
|
TALS Important Levels Intraday
RESISTANCE | 2.94 |
RESISTANCE | 2.81 |
RESISTANCE | 2.74 |
RESISTANCE | 2.66 |
SUPPORT | 2.44 |
SUPPORT | 2.36 |
SUPPORT | 2.29 |
SUPPORT | 2.16 |
TALS Forecast May 2024
4th UP Forecast | 17.72 |
3rd UP Forecast | 12.85 |
2nd UP Forecast | 9.85 |
1st UP Forecast | 6.84 |
1st DOWN Forecast | -1.74 |
2nd DOWN Forecast | -4.75 |
3rd DOWN Forecast | -7.75 |
4th DOWN Forecast | -12.62 |
TALS Weekly Forecast
4th UP Forecast | 6.02 |
3rd UP Forecast | 4.91 |
2nd UP Forecast | 4.22 |
1st UP Forecast | 3.53 |
1st DOWN Forecast | 1.57 |
2nd DOWN Forecast | 0.88 |
3rd DOWN Forecast | 0.19 |
4th DOWN Forecast | -0.92 |
TALS Forecast2024
4th UP Forecast | 32.84 |
3rd UP Forecast | 23.13 |
2nd UP Forecast | 17.12 |
1st UP Forecast | 11.12 |
1st DOWN Forecast | -6.02 |
2nd DOWN Forecast | -12.02 |
3rd DOWN Forecast | -18.03 |
4th DOWN Forecast | -27.74 |
Talaris Therapeutics Inc ( NASDAQ USA Symbol : TALS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
TALS Other Details
Segment | EQ | |
Market Capital | 672285120.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
TALS Address
TALS Latest News
TALS Business Profile
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky. Address: 570 South Preston Street, Louisville, KY, United States, 40202
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service